https://kstockbriefing.com
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics announced an amendment modifying both the contract period end date and the non-disclosure deadline for a contract manufacturing LOI signed with a European pharmaceutical company to October 31, 2024. 📊 [Key Disclosure Details & Summary Statistics] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Tracking…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics announced an amendment modifying both the contract period end date and the non-disclosure deadline for a contract manufacturing LOI signed with a European pharmaceutical company to October 31, 2024. 📊 [Key Disclosure Details & Summary Statistics] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Tracking…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics announced that the defendants (the Securities and Futures Commission and the Financial Services Commission) have filed an appeal against the first-instance court ruling that was in favor of Samsung Biologics regarding administrative disposition cancellations. 📊 [Key Disclosure Details & Summary Statistics] 📝 Editor’s Comment…
Read More “[Disclosure] Samsung Biologics (207940) – Major Management Matters / 2024-08-28” »
![[Disclosure] Celltrion (068270) – Application for Phase 3 Clinical Trial Plan for CT-P13 SC (Zymfentra) in Europe (Part 1 & 2) (Rheumatoid Arthritis) / 2024-08-27](https://kstockbriefing.com/wp-content/uploads/2026/08/포맷변환셀트리온.jpg)
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced that it has submitted an application for a global Phase 3 clinical trial plan (Part 1 & Part 2) to the European Medicines Agency (EMA) to evaluate the efficacy and safety of CT-P13 SC (Zymfentra) in patients with rheumatoid arthritis. 📊 [Key Disclosure Details…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced that it has received final marketing authorization from the European Commission (EC) for Steqeyma (CT-P43), a biosimilar to Stelara, covering 30 European countries for indications including plaque psoriasis and Crohn’s disease. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint)…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced that it has submitted an application for a global Phase 3 clinical trial plan (Part 1 & Part 2) to the European Medicines Agency (EMA) to evaluate the efficacy and safety of CT-P51 compared with Keytruda in patients with non-small cell lung cancer. 📊…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced that the U.S. Food and Drug Administration (FDA) has approved its global Phase 3 clinical trial plan for CT-P13 SC (Zymfentra) to evaluate efficacy and safety in patients with rheumatoid arthritis. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint)…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics announced a disclosure correction following a favorable first-instance ruling by the Seoul Administrative Court, which ruled to revoke the administrative dispositions imposed by the Securities and Futures Commission and the Financial Services Commission in 2018. 📊 [Key Disclosure Details & Summary Statistics] 📝 Editor’s…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced that the U.S. Food and Drug Administration (FDA) has approved its global Phase 3 clinical trial plan for CT-P55 to evaluate efficacy and safety compared with Cosentyx in patients with plaque psoriasis. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced that the U.S. Food and Drug Administration (FDA) has approved its global Phase 3 clinical trial plan for CT-P51 to evaluate efficacy and safety compared with Keytruda in patients with non-small cell lung cancer. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment…